Association of sleep among 30 antidepressants: a population-wide adverse drug reaction study, 2004–2019

Andy R. Eugene

Independent Researcher, Kansas, United States of America
Independent Neurophysiology Unit, Department of Psychiatry, Medical University of Lublin, Lublin, Poland

ABSTRACT

Background. Sleep is one of the most essential processes required to maintain a healthy human life, and patients experiencing psychiatric illness often experience an inability to sleep. The aim of this study is to test the hypothesis that antidepressant compounds with strong binding affinities for the serotonin 5-HT2C receptor, histamine H1 receptors, or norepinephrine transporter (NET) will be associated with the highest odds of somnolence.

Methods. Post-marketing cases of patient adverse drug reactions were obtained from the United States Food and Drug Administration Adverse Events Reporting System (FAERS) during the reporting window of January 2004 to September 2019. Disproportionality analyses of antidepressants reporting somnolence were calculated using the case/non-case method. The reporting odds-ratios (ROR) and corresponding 95% confidence interval (95% CI) were computed and all computations and graphing conducted in R.

Results. There were a total of 69,196 reported cases of somnolence out of a total of 7,366,864 cases reported from January 2004 to September 2019. Among the 30 antidepressants assessed, amoxapine (n = 16) reporting odds-ratio (ROR) = 7.1 (95% confidence interval [CI] [4.3–11.7]), atomoxetine (n = 1,079) ROR = 6.6 (95% CI [6.2–7.1]), a compound generally approved for attention deficit hyperactivity disorder (ADHD), and maprotiline (n = 18) ROR = 6.3 (95% CI, 3.9–10.1) were the top three compounds ranked with the highest reporting odds of somnolence. In contrast, vortioxetine (n = 52) ROR = 1.3 (95% CI [1.0–1.8]), milnacipran (n = 58) ROR = 2.1 (95% CI [1.7–2.8]), and bupropion (n = 1,048) ROR = 2.2 (95% CI [2.1–2.4]) are least significantly associated with somnolence. Moreover, levomilnacipran (n = 1) ROR = 0.4 (95% CI [0.1–2.9]) was not associated with somnolence.

Conclusion. Among the thirty tested antidepressants, consistent with the original hypothesis, amoxapine has strongest 5-HT2C receptor binding affinity and has the highest reporting odds of somnolence. Atomoxetine, ranked second in reporting odds of somnolence overall, binds to the NET with with the strongest binding affinity among the thirty compounds. Mirtazapine, a tetracyclic antidepressant, was ranked 11th in reporting odds of somnolence and had the strongest H1 receptor binding affinity. This study provides an informative ranking of somnolence among thirty antidepressant compounds with an already wide array of clinical indications as well as provides insight into potential drug repurposing in psychopharmacology.
INTRODUCTION

The inability to sleep, or insomnia, has been historically reported in patients experiencing depression, anxiety, alcoholism, suicidal ideation, suicide attempts, and substance abuse (Roane & Taylor, 2008; Brower, 2003; Chakravorty et al., 2014; Don Richardson et al., 2018; Taylor et al., 2005; Yaya et al., 2018). In fact, sleeping disturbances may be so pervasive in chronic cases of the aforementioned patient groups, that the most recently approved antidepressant compound, indicated for treatment-resistant depression and intended to be used in conjunction with an oral antidepressant, is the S-enantiomer of ketamine, a racemic compound of R- and S-ketamine which is used in anesthesia (DailyMed., 2019b; White et al., 1985). Similarly, another effective compound used in treating patients with treatment-resistant depression and depressive episodes associated with Bipolar I Disorder, combines olanzapine, an antipsychotic that shows gender differences when binding to the dopamine D2, with fluoxetine and recommended to be administered nightly due to olanzapine’s impact on sleep (DailyMed., 2019a; Eugene & Masiak, 2017; Lazowski et al., 2014).

Sleep is reported to be neuroprotective by clearing out metabolic waste products via the brain’s glymphatic system and a recent systematic review and meta-analysis found that exercise improves the quality of sleep (Banno et al., 2018; Eugene & Masiak, 2015; Xie et al., 2013). Antidepressants are prescribed for an array of clinical indications and differ in pharmacokinetics and pharmacodynamics (Eugene, 2019; Wong et al., 2016). Irrespective of the clinical diagnoses for which an antidepressant compound is indicated, as a result of modulation of monoamine transporters (e.g., norepinephrine (NET), serotonin (SERT), and dopamine (DAT)), binding at various receptor affinities (Ki), altering gene expression, as well as other factors, certain adverse drug reactions are categorically common amongst antidepressants (Eugene, 2019; Eugene, Masiak & Eugene, 2018; Owens et al., 1997; Qin et al., 2019). The term somnolence derives from French and Latin meaning to sleep. In patients who are prescribed antidepressants and operate heavy machinery, work in aviation, or require alertness in their profession, excessive somnolence may result in severe adverse outcomes. Similarly, in patients who suffer from major depressive disorder and experience comorbid symptoms of insomnia, anxiety, intrusive and obsessive thoughts, compulsive behaviors, or agitation, antidepressants with off-target pharmacodynamic effects that induce somnolence may be beneficial. Thus, a comparative analysis ranking antidepressants based on the highest and lowest odds of somnolence is an unmet clinical need and informative.

Sleep is one of the most essential processes required to maintain a healthy human life (Cirelli, 2006; Hobson, 2005). Various receptors are implicated when considering effects on somnolence. Compounds blocking alpha-1 adrenergic receptor, histaminergic receptors...
(H1), muscarinic cholinergic receptors, N-methyl-D-aspartate (NMDA) receptors thereby decreasing glutamate, and also compounds blocking melatoninergic receptors leading to an increase in γ-aminobutyric acid (GABA) concentrations, are all well-established to promote sleep (Watson, Baghdoyan & Lydic, 2010; Watson, Baghdoyan & Lydic, 2012). Further, slow wave sleep is found to be predominately mediated by the serotonin 2C (5-HT2C) receptors that are found in the choroid plexus and is the same neuroanatomical location of the alpha-1 adrenergic receptors that promote clearance of metabolic waste from the brain (Sharpley et al., 1994; Szot, 2016). Among various cellular and physiological processes occurring during sleep, a key component is the activation of the brain’s neuroprotective glymphatic system (Jessen et al., 2015). The catecholamine neurotransmitter norepinephrine is established as the primary neurotransmitter that suppresses the brain’s glymphatic system when awake by inhibiting the choroid plexus cerebral spinal fluid flow (Jessen et al., 2015). Psychotropic medications with relatively potent alpha-1 adrenergic receptors binding affinities, selectively inhibit the norepinephrine reuptake transporters, or have a strong affinity for the 5-HT2C receptors in the choroid plexus all have the potential to influence the clearance of the brain’s metabolic waste products improving cognition and sleep (Szot, 2016; Xie et al., 2013).

With this information as a background, the aim of this study is to test the hypothesis that antidepressant compounds with low Ki values—that is strong receptor binding affinities—for the serotonin 5-HT2C receptor, histamine (H1) receptors, or norepinephrine transporter (NET) will be associated with the highest odds of somnolence. To test this hypothesis, I will use post-marketing pharmacovigilance cases reported to the Food and Drug Administration MedWatch program and conduct disproportionality analysis.

**MATERIALS & METHODS**

Adverse drug event cases were obtained from post-marketing adverse drug reactions reported to the MedWatch program enacted by the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS) (United States Food and Drug Administration, 2018). Institutional Review Board approval was not required due to patient cases being de-identified and available from the FDA website (https://www.fda.gov). Patient cases included all age groups from FAERS reports originating from the first quarter of 2004 and ending in the third quarter of 2019. The primary outcome variable is the reporting odds-ratios of the following thirty antidepressant compounds: amitriptyline, amoxepine, atomoxetine, bupropion, citalopram, clomipramine, desvenlafaxine, doxepin, duloxetine, escitalopram, esetamibe, fluoxetine, fluvoxamine, imipramine, levomilnacipran, maprotiline, mianserin, milnacipran, mirtazapine, nortriptyline, olanzapine/fluoxetine, paroxetine, phenelzine, selegiline, sertraline, tanylcypromine, trazodone, venlafaxine, vilazodone, and vortioxetine. Somnolence is the coded preferred term referenced from the Medical Dictionary for Regulatory Activities (MedDRA) for analysis in this study (Brown, Wood & Wood, 1999). In a secondary analysis, the thirty antidepressant compounds are grouped based on the following pharmacological drug class and assessed for reporting odds of somnolence: atypical antipsychotic/ selective serotonin reuptake
inhibitor, monoamine oxidase inhibitors, non-competitive N-methyl-D-aspartate receptor antagonist, norepinephrine reuptake inhibitor, norepinephrine-dopamine reuptake inhibitor, selective serotonin reuptake inhibitors, serotonin antagonist and reuptake inhibitor, serotonin modulator and stimulators, serotonin-norepinephrine reuptake inhibitors, tetracyclic antidepressants, and tricyclic antidepressants.

**Drug-gene associations**

Human phase I and phase II drug metabolizing enzyme data that includes cytochrome P450 (CYP) inhibitor or inducer information are referenced from the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology Update 2017 and the FDA Drug Development and Drug Interactions Table of Substrates, Inhibitors and Inducers (*CDER, 2017; Hefner, 2018*).

**Statistical analysis**

Disproportionality analyses of psychotropic adverse events resulting in somnolence were calculated using Fisher’s exact test, via a two-by-two contingency table, using the case/non-case method (*Egberts, Meyboom & Van Puijenbroek, 2002; Rochoy et al., 2018*). A minimum of 1 case is required and the final estimated reporting odds-ratios (ROR) and corresponding 95% confidence interval (95% CI) are reported in the text. All graphical illustrations as well as all computations were performed using R (version 3.5.2, R Foundation for Statistical Computing, Vienna, Austria) (*Böhm et al., 2016; R Core Team, 2013*). The reporting odds-ratio-95% confidence intervals not crossing a value of one is interpreted as statistically significant.

**RESULTS**

From January 2004 to September 2019 there were a total of 7,366,864 cases reported to the FDA Adverse Events Reporting System with 69,196 cases specifically reported as somnolence. Duloxetine (*n* = 1,710) ROR = 3.0 (95% CI [2.8–3.1]) was the antidepressant with the most reported cases of somnolence, while levomilnacipran (*n* = 1) ROR = 0.4 (95% CI [0.1–2.9]) had only one reported case of somnolence and not significantly associated with the adverse event. Amoxapine (*n* = 16) ROR = 7.1 (4.3–11.7), a metabolite of the antipsychotic loxapine, had the highest reporting odds of somnolence among the study compounds. Whereas, atomoxetine (*n* = 1,079) ROR = 6.6 (95% CI [6.2–7.1]), a norepinephrine reuptake inhibitor and primarily approved for attention deficit hyperactivity disorder (ADHD), was found to have the second strongest association with somnolence. Vortioxetine (*n* = 50) ROR = 1.3 (95% CI [1.0–1.8]) was least statistically significantly associated with somnolence among thirty testing antidepressant compounds.

Two marketed antidepressant compounds mainly in treatment-resistant depression were found to have an equal reporting odds-ratio of somnolence: olanzapine/floxetine (*n* = 95) ROR = 3.8 (95% CI [3.1–4.7]) and esketamine (*n* = 12) ROR = 3.8 (95% CI [2.1–6.7]). Several compounds, seven groups totaling eighteen antidepressants, were found to have equal reporting odds of somnolence and the results are available in Table 1, sorted from highest to lowest reporting odds of somnolence. Figure 1 illustrates the forest plots
There were a total of 69,196 reports of somnolence and 7,366,864 total cases reported overall from January 2004 to September 30, 2019 to the Food and Drug Administration Adverse Events Reporting System.

| Antidepressant                  | Somnolence cases | Other reported cases | Somnolence ROR (95% CI) | Antidepressant classification                        |
|--------------------------------|------------------|----------------------|-------------------------|------------------------------------------------------|
| Amoxapine                      | 16               | 239                  | 7.1 (4.3–11.7)          | Tetracyclic antidepressant                           |
| Atomoxetine                    | 1,079            | 17,353               | 6.6 (6.2–7.1)           | Norepinephrine reuptake inhibitor                    |
| Maprotiline                    | 18               | 302                  | 6.3 (3.9–10.1)          | Tetracyclic antidepressant                           |
| Mianserin                      | 33               | 587                  | 5.9 (4.2–8.4)           | Tetracyclic antidepressant                           |
| Phencicline                    | 55               | 1,150                | 5.0 (3.9–6.6)           | Monoamine oxidase inhibitor                          |
| Clomipramine                   | 111              | 2,794                | 4.2 (3.5–5.1)           | Tricyclic antidepressant                             |
| Fluvoxamine                    | 116              | 2,985                | 4.1 (3.4–4.9)           | Selective serotonin reuptake inhibitor               |
| Olanzapine/Fluoxetine          | 95               | 2,647                | 3.8 (3.1–4.7)           | Atypical antipsychotic/Selective serotonin reuptake inhibitor |
| Escetamine                     | 12               | 337                  | 3.8 (2.1–6.7)           | Non-competitive N-methyl-D-aspartate receptor antagonist |
| Imipramine                     | 82               | 2,401                | 3.6 (2.9–4.5)           | Tricyclic antidepressant                             |
| Mirtazapine                    | 827              | 24,504               | 3.6 (3.3–3.8)           | Tetracyclic antidepressant                           |
| Dooxepin                       | 139              | 4,283                | 3.4 (2.9–4.1)           | Tricyclic antidepressant                             |
| Escitalopram                   | 1,175            | 39,569               | 3.2 (3.0–3.4)           | Selective serotonin reuptake inhibitor               |
| Desvenlafaxine                 | 492              | 16,521               | 3.2 (2.9–3.5)           | Serotonin-norepinephrine reuptake inhibitor          |
| Nortriptyline                  | 166              | 5,611                | 3.1 (2.7–3.6)           | Tricyclic antidepressant                             |
| Paroxetine                     | 1,537            | 53,007               | 3.1 (2.9–3.3)           | Selective serotonin reuptake inhibitor               |
| Venlafaxine                    | 1,543            | 53,349               | 3.1 (2.9–3.3)           | Serotonin-norepinephrine reuptake inhibitor          |
| Citalopram                     | 1,248            | 44,505               | 3.0 (2.8–3.2)           | Selective serotonin reuptake inhibitor               |
| Vilazodone                     | 70               | 2,474                | 3.0 (2.4–3.8)           | Serotonin modulator and stimulator                   |
| Duloxetine                     | 1,710            | 61,438               | 3.0 (2.8–3.1)           | Serotonin-norepinephrine reuptake inhibitor          |
| Selegiline                     | 40               | 1,521                | 2.8 (2.0–3.8)           | Monoamine oxidase inhibitor                          |
| Trazodone                      | 721              | 27,640               | 2.8 (2.6–3.0)           | Serotonin antagonist and reuptake inhibitor          |
| Amitriptyline                  | 676              | 25,920               | 2.8 (2.6–3.0)           | Tricyclic antidepressant                             |
| Tranylcypromine                | 15               | 583                  | 2.7 (1.6–4.5)           | Monoamine oxidase inhibitor                          |
| Fluoxetine                     | 1,037            | 42,066               | 2.6 (2.5–2.8)           | Selective serotonin reuptake inhibitor               |
| Sertraline                     | 1,638            | 67,904               | 2.6 (2.5–2.7)           | Selective serotonin reuptake inhibitor               |
| Bupropion                      | 1,048            | 49,599               | 2.2 (2.1–2.4)           | Norepinephrine-dopamine reuptake inhibitor          |
| Milnacipran                    | 58               | 2,858                | 2.1 (1.7–2.8)           | Serotonin-norepinephrine reuptake inhibitor          |
| Vortioxetine                   | 52               | 4,075                | 1.3 (1.0–1.8)           | Serotonin modulator and stimulator                   |
| Levomilnacipran                | 1                | 260                  | 0.4 (0.1–2.9)           | Serotonin-norepinephrine reuptake inhibitor         |

of the thirty antidepressants compounds ranked based on reporting odds of somnolence to the FAERS.

When grouping the compounds based on pharmacological class, the selective serotonin reuptake inhibitor (SSRI) class of antidepressants had the most reported cases of somnolence ($n = 6,751$) ROR = 3.1 (95% CI [3.0–3.1]). Moreover, least number of somnolence cases was the non-competitive NMDA class and shown above for esketamine. The norepinephrine reuptake inhibitor atomoxetine, reported above, was associated with the highest reporting odds of somnolence. The serotonin modulator and stimulators
Reporting Odds Ratio with 95% Confidence Interval of Somnolence

Figure 1  Association of somnolence among 30 antidepressants compounds. Forest plots illustrating reporting odds-ratios (ROR) and 95% confidence intervals of antidepressants ranked from the highest to lowest reporting odds of somnolence reported to the Food and Drug Administration Adverse Events Reporting System during January 2004 and September 2019.

Table 2 and Fig. 2 provide the final statistical findings and graphical illustration of the eleven antidepressant classes in this study.

DISCUSSION

Somnolence and 5-HT2C, NET, and Alpha-1 adrenergic receptor binding affinities

This study assessed and ranked the reporting odds of somnolence among thirty antidepressant compounds using post-marketing adverse drug reactions reported to the FAERS. As shown in Table 1, seven groups of antidepressants resulted in equivalent reporting odds of somnolence. Consistent with the original hypothesis, the compound with the highest reporting odds of somnolence indeed has the strongest 5-HT2C receptor binding affinity, amoxapine (Ki = 2 nM), among the 30 antidepressant compounds tested (Roth et al., 2000; Tatsumi et al., 1997). Further, amoxapine’s binding affinities for NET
Table 2  Reporting Odds-Ratios (ROR) and 95% confidence intervals of 30 antidepressant compounds based on antidepressant classification included in the study.

| Antidepressant classification                                      | Somnolence cases | Other reported cases | Somnolence ROR (95% CI) |
|-------------------------------------------------------------------|------------------|----------------------|------------------------|
| Norepinephrine reuptake inhibitor (n = 1)                         | 1,079            | 17,353               | 6.6 (6.2–7.1)          |
| Atypical antipsychotic/Selective serotonin reuptake inhibitor (n = 1) | 95               | 2,647                | 3.8 (3.1–4.7)          |
| Non-competitive N-methyl-D-aspartate receptor antagonist (n = 1)  | 12               | 337                  | 3.8 (2.1–6.7)          |
| Tetracyclic antidepressants (n = 4)                              | 894              | 25,632               | 3.7 (3.5–4.0)          |
| Monoamine oxidase inhibitors (n = 3)                             | 110              | 3,254                | 3.6 (3.0–4.3)          |
| Serotonin-norepinephrine reuptake inhibitors (n = 5)              | 3,804            | 134,426              | 3.1 (3.0–3.2)          |
| Selective serotonin reuptake inhibitors (n = 6)                  | 6,751            | 250,036              | 3.1 (3.0–3.1)          |
| Tricyclic antidepressants (n = 5)                                | 1,174            | 41,009               | 3.1 (2.9–3.2)          |
| Serotonin antagonist and reuptake inhibitor (n = 1)               | 721              | 27,640               | 2.8 (2.6–3.0)          |
| Norepinephrine-dopamine reuptake inhibitor (n = 1)               | 1,048            | 49,599               | 2.2 (2.1–2.4)          |
| Serotonin modulator and stimulators (n = 2)                      | 122              | 6,549                | 2.0 (1.6–2.4)          |

Figure 2  Association of somnolence based on antidepressant class from 30 compounds. Forest plots illustrating reporting odds-ratios (ROR) and 95% confidence intervals of antidepressant class ranked from the highest to lowest reporting odds of somnolence reported to the Food and Drug Administration Adverse Events Reporting System during January 2004 and September 2019. NMDA indicates N-methyl-D-aspartate.
and H1 receptor are $K_i = 16 \text{nM}$ and $25 \text{nM}$, respectively. Atomoxetine, a norepinephrine reuptake inhibitor and generally indicated in patients with ADHD, was ranked second in somnolence overall and binds to the NET with the lowest $K_i$ value of $3.5 \text{nM}$ among the thirty antidepressant compounds in this study (Roth et al., 2000; Tatsumi et al., 1997). Mirtazapine, a tetracyclic antidepressant, was ranked 11th in reporting odds of somnolence and had the strongest H1 receptor binding affinity with a $K_i$ of $0.14 \text{nM}$ (Roth et al., 2000; Tatsumi et al., 1997). When considering the glymphatic system, doxepin was the antidepressant compound with the lowest alpha-1 adrenergic receptor binding affinity ($K_i = 23.4 \text{nM}$) and ranked 12th in reporting odds of somnolence ($n = 139$ ROR = 3.4 (95% CI [2.9–4.1]), but also has a low H1 receptor $K_i$ value of $0.24 \text{nM}$ (Roth et al., 2000; Tatsumi et al., 1997).

Maprotiline, a tetracyclic antidepressant, was ranked third among the thirty antidepressants and binds to the H1 receptor ($K_i = 1.7 \text{nM}$) and NET ($K_i = 11.1 \text{nM}$) with high affinity (Roth et al., 2000; Tatsumi et al., 1997). Similarly, mianserin, another tetracyclic antidepressant, binds to the 5-HT2C and H1 receptors with $K_i$ values of $2.59 \text{nM}$ and $1 \text{nM}$, respectively (Roth et al., 2000; Tatsumi et al., 1997). In contrast, vortioxetine, a serotonin modulator and stimulator, was least associated with somnolence and potently inhibits the serotonin transporter (SERT) with a $K_i = 1.6 \text{nM}$, however weakly binds to the 5-HT2C receptor with a $K_i = 180 \text{nM}$ and the NET with a $K_i = 113 \text{nM}$ (D’Agostino, English & Rey, 2015; Di & Kerns, 2015; Roth et al., 2000).

A recent meta-analysis that analyzed 276 studies and 14 second-generation antidepressants, evaluated somnolence in patients undergoing treatment for major depression, reported that fluvoxamine ($K_i = 1,892 \text{nM}$, 5-HT2C $K_i = 6,700 \text{nM}$) and mirtazapine (H1 inverse agonist $K_i=0.14 \text{nM}$, 5-HT2C $K_i = 39 \text{nM}$) resulted in the highest odds of somnolence (Alberti et al., 2015). Moreover, in the same study, bupropion ($K_i = 5,600 \text{nM}$, H1 = 6,700 NM) was reported to have the lowest odds of somnolence and highest odds of insomnia (Alberti et al., 2015; Roth et al., 2000). Nevertheless, the odds of causing somnolence are not related to popularity index of antidepressants. A recent scientometric analysis reported that fluoxetine has the highest popularity index (4.0) (Tran et al., 2019). The popularity indexes of aforementioned antidepressants are as follows: fluvoxamine (1.00), bupropion (0.71), mirtazapine (0.61), vortioxetine (0.1), desvenlafaxine (0.08), vilazodone (0.04) and levomilnacipran (0.03). (Tran et al., 2019).

**Antidepressant-associated somnolence and CYP2C19 poor metabolizers**

Patients who are CYP2C19 Poor Metabolizers—that is have single-nucleotide polymorphisms (SNPs) allele combinations of CYP2C19 *2/*2-3 and have a fraction of activity (FA) of 0.005—when compared to CYP219 Normal Metabolizers (*1/*1 FA = 1 and *2-3/*17 FA = 0.8) will have an increase in drug exposure (Fermier et al., 2018). The allele frequency of the functionally inactive CYP2C19*2 variant is seen at rates of 18.1% in African, 10.1% in Admixed American, 18.3% in European, 31.0% in East Asian, and 34.0% in Southeast Asian populations (Zhou, Ingelman-Sundberg & Lauschke, 2017). Based on the study results, the antidepressant compounds with the highest reporting odds of somnolence...
and not primarily metabolized by CYP2C19 substrates are: vilazodone, mirtazapine, and duloxetine. Further, antidepressants with the lowest reporting odds of somnolence and not primarily metabolized by CYP2C19 are: levomilnacipran, milnacipran, vortioxetine, and buproprion.

**Antidepressant-associated somnolence and CYP2D6 poor metabolizers**

Increased drug exposures are also evident in patients who are prescribed CYP2D6 drug substrates and have CYP2D6 loss-of-function DNA sequence variants leading to being phenotypically classified as CYP2D6 Poor Metabolizers (*3-8/*3-8 FA = 0.01 and *10/*10 FA = 0.1) (Fermier et al., 2018). The CYP2D6*4 functionally inactive variant has the highest allele frequency rate and is seen in 11.9% in African, 15.7% in Admixed American, 15.5% in European, 0.4% in East Asian, and 11.6% in Southeast Asian populations (Zhou, Ingelman-Sundberg & Lauschke, 2017). The CYP2D6*5 inactive variant is seen at a 6.5% allele frequency in the Southeast Asian population (Zhou, Ingelman-Sundberg & Lauschke, 2017). Based on the study results, milnacipran and levomilnacipran are antidepressant compounds with low and no association with somnolence, respectively. Further, tablet-based antidepressants that are significantly associated with somnolence and have no to minor CYP2D6 contribution are: desvenlafaxine and mirtazapine. Esketamine is FDA approved in conjunction with an oral antidepressant (DailyMed., 2019b).

**Pharmacogenomics, therapeutic drug monitoring, and clinical pharmacologists**

In cases where CYP450 metabolizer status are unknown or even unclear from pharmacogenomic testing reports due to concomitant medications resulting in drug-drug-gene interactions, directly measuring drug plasma concentrations via therapeutic drug monitoring (TDM) is often most efficient (Eugene & Eugene, 2018; Qin et al., 2019). Of note, CYP2C19 *1/*2-3 (FA = 0.3) genotypes are phenotypically CYP2C19 Intermediate Metabolizers and known to have a reduced fraction of activity relative to CYP2C19 Normal Metabolizers (FA = 1) (Fermier et al., 2018). In contrast, excessive metabolic rates, resulting in sub-therapeutic antidepressant plasma concentrations, are seen in patients who are CYP2C19 Ultra-rapid Metabolizers and have variant combinations of CYP2C19 *17/*17 (FA = 2.03) and *1/*17 (FA = 1.59) (Fermier et al., 2018). Thus, when considering the results for selecting an antidepressant with an association with somnolence, or even extrapolating from other studies, there may be wide inter-individual variability in antidepressant therapeutic effect and adverse effect. More importantly, the United States Food and Drug Administration expresses concern to physicians and other healthcare professionals that the association of current pharmacogenomics testing reports and antidepressant efficacy are not yet established (FDA, 2018).

In various countries, physicians specializing in clinical pharmacology routinely utilize pharmacogenomics as a means to avoid drug toxicity by mainly using TDM, applying Bayesian dosing methods, and other techniques with the aim of patient drug safety (Borobia et al., 2017; Eichelbaum, Dahl & Sjöqvist, 2018). In the U.S., there needs to be a significant increase in clinical pharmacology training programs that provide direct entry following
medical school, as is done internationally, to have more clinical pharmacologists within the hospitals to carry out traditional patient care roles, consult with other physicians, interpret the pharmacogenomics testing reports, and advance the field. One major limitation of using pharmacogenomics testing reports alone to guide drug decision-making is that most patients are prescribed more than one medication resulting in drug-drug interactions as well as drug-drug-gene interactions. Whereas, adding TDM will increase precision in dosing and avoid toxicity based on established safety plasma ranges using pharmacokinetics (Hefner, 2018). Further, drug selection based on pharmacogenomics testing reports alone without also accounting for established efficacy is that often pharmacogenomic testing systematically recommends CYP3A4 substrate alone, as well as compounds not dependent on cytochrome P450 oxidative metabolism, despite established therapeutic efficacy for all compounds that gained regulatory approval. More specifically, a pharmacogenomics study found that among twenty-two antidepressants, desvenlafaxine and levomilnacipran (renally excreted) were recommended greater than 90% of the time, while in less than 10.5% of the time citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, and sertraline were never in the green (i.e., use as directed) category (Macaluso & Preskorn, 2018). However, in a systematic review and network meta-analysis comprised of 522 clinical trials with 116,477 participants found that (in order of decreased efficacy): amitriptyline, mirtazapine, duloxetine, venlafaxine, paroxetine, milnacipran, fluvoxamine, escitalopram, nefazodone, and sertraline were the top ten most efficacious; while levomilnacipran ranked 14th and desvenlafaxine was ranked 20th out of the 21 assessed antidepressants in the study (Cipriani et al., 2018).

**Study limitations**

The study limitations are that the reporting odds-ratios are generally hypothesis generating due to the entire population of patients experiencing the side-effect are not known, but are dependent on voluntary submission of the adverse event to the FDA. Further, the term somnolence may be reported and recorded as sedation and this study did not factor in the term sedation in the analysis. For example, in the adverse reactions section of atomoxetine’s package insert states that both somnolence and sedation was recorded as somnolence (DailyMed., 2018). For the newest compound in this study, the FAERS results for esketamine showed 61 adverse events for sedation, 288 as other cases, and 349 total reported cases resulting in a ROR = 140 (95% CI [111–176]) for sedation alone. Statistically, the overall interpretation of the results are that the strength of the ADR association with the drugs-under-test and are not indicative of risk (Montastruc et al., 2011). Further, psychotropic medications exhibit target and off-target effects influencing the cholinergic (acetylcholine), gamma-aminobutyric acid (GABA)-ergic, glutaminergic (glutamate), glycnergic, and L-Arginine nitric oxide pathways, among others, so the association of somnolence may not be directly associated with the glymphatic system alone.
CONCLUSIONS

The top three antidepressant compounds with the strongest reporting odds of somnolence are amoxapine, atomoxetine, and maprotiline. Levomilnacipran was not associated with somnolence. Vortioxetine, milnacipran, and bupropion were least associated with somnolence. Consistent with the original hypothesis, amoxapine has strongest 5-HT2C receptor binding affinity and has the highest reporting odds of somnolence. Atomoxetine, ranked second in reporting odds of somnolence, binds to the NET with the strongest binding affinity. Lastly, mirtazapine has the strongest H1 receptor binding affinity among the thirty antidepressant compounds and was ranked 11th in reporting odds of somnolence. This study provides an informative ranking of reporting odds of somnolence among thirty antidepressant compounds with an already wide array of clinical indications and provides insight to potential drug repurposing in psychopharmacology.

ACKNOWLEDGEMENTS

The author acknowledges Dr. Beata Eugene, PhD at the Maria Curie-Sklodowska University in Lublin, Poland. The author also acknowledges the FDA Adverse Events Reporting System.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
The author received no funding for this work.

Competing Interests
The author declares there are no competing interests.

Author Contributions

• Andy R. Eugene conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:

Cases reported in this article are freely available from the United States Food and Drug Administration and may be downloaded here: https://www.fda.gov/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files.

REFERENCES

Alberti S, Chiesa A, Andrisano C, Serretti A. 2015. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression. Journal of Clinical Psychopharmacology 35:296–303 DOI 10.1097/JCP.0000000000000329.
Banno M, Harada Y, Taniguchi M, Tobita R, Tsujimoto H, Tsujimoto Y, Kataoka Y, Noda A. 2018. Exercise can improve sleep quality: a systematic review and meta-analysis. *PeerJ* **6**:e5172 DOI 10.7717/peerj.5172.

Böhm R, Von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, Höcker J. 2016. OpenVigil FDA—inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. *PLOS ONE* **11**:e0157753 DOI 10.1371/journal.pone.0157753.

Borobia AM, Dapia I, Tong HY, Arias P, Muñoz M, Tenorio J, Hernández R, García García I, Gordo G, Ramírez E, Frias J, Lapunzina P, Carcas AJ. 2017. Clinical implementation of pharmacogenetic testing in a hospital of the Spanish national health system: strategy and experience over 3 years. *Clinical and Translational Science* **11**:189–199.

Brower KJ. 2003. Insomnia, alcoholism and relapse. *Sleep Medicine Reviews* **7**:523–539 DOI 10.1016/S1087-0792(03)90005-0.

Brown EG, Wood L, Wood S. 1999. The medical dictionary for regulatory activities (MedDRA). *Drug Safety* **20**:109–117 DOI 10.2165/00002018-199920020-00002.

Center for Drug Evaluation and Research (CDER). 2017. Drug interactions & labeling—drug development and drug interactions: table of substrates, inhibitors and inducers. Available at https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm (accessed on 3 March 2019).

Chakravorty S, Grandner MA, Mavandadi S, Perlis ML, Sturgis EB, Oslin DW. 2014. Suicidal ideation in Veterans misusing alcohol: relationships with insomnia symptoms and sleep duration. *Addictive Behaviors* **39**:399–405 DOI 10.1016/j.addbeh.2013.09.022.

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* **391**:1357–1366 DOI 10.1016/S0140-6736(17)32802-7.

Cirelli C. 2006. Cellular consequences of sleep deprivation in the brain. *Sleep Medicine Reviews* **10**:307–321 DOI 10.1016/j.smrv.2006.04.001.

D’Agostino A, English CD, Rey JA. 2015. Vortioxetine (brintellix): a new serotonergic antidepressant. *P & T* **40**:36–40.

DailyMed. 2018. STRATTERA-atomoxetine hydrochloride capsule. U.S. National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb (accessed on 23 January 2020).

DailyMed. 2019a. SYMBYAX (olanzapine and fluoxetine hydrochloride) capsule. National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b28c424-0.7e-4b75-0f116b113554e (accessed on 24 January 2020).
DailyMed. 2019b. SPRAVATO-esketamine hydrochloride solution. National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eadf (accessed on 23 January 2020).

Di L, Kerns EH. 2015. Blood-brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs. Hoboken: Wiley DOI 10.1002/9781118788523.

Don Richardson J, King L, St. Cyr K, Shnaider P, Roth ML, Ketcheson F, Balderson K, Elhai JD. 2018. Depression and the relationship between sleep disturbances, nightmares, and suicidal ideation in treatment-seeking Canadian Armed Forces members and veterans. BMC Psychiatry 18:204 DOI 10.1186/s12888-018-1782-z.

Egberts ACG, Meyboom RHB, Van Puijenbroek EP. 2002. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Safety 25(6):453–458 DOI 10.2165/00002018-200225060-00010.

Eichelbaum M, Dahl ML, Sjöqvist F. 2018. Clinical pharmacology in Stockholm 50 years—report from the jubilee symposium. European Journal of Clinical Pharmacology 74:843–851 DOI 10.1007/s00228-018-2432-6.

Eugene AR. 2019. Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors. PeerJ 7:e7860 DOI 10.7717/peerj.7860.

Eugene AR, Eugene B. 2018. An opportunity for clinical pharmacology trained physicians to improve patient drug safety: a retrospective analysis of adverse drug reactions in teenagers. F1000 Research 7:677 DOI 10.12688/f1000research.14970.2.

Eugene AR, Masiak J. 2015. The neuroprotective aspects of sleep. MEDtube Sci 3:35–40.

Eugene AR, Masiak J. 2017. A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy. Nordic Journal of Psychiatry 71:417–424 DOI 10.1080/08039488.2017.1314011.

Eugene AR, Masiak J, Eugene B. 2018. Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning. F1000 Research 7:474 DOI 10.12688/f1000research.14451.3.

Food and Drug Administration (FDA). 2018. Jeffrey Shuren M.D., J.D., director of the FDA’s Center for Devices and Radiological Health and Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research on agency’s warning to consumers about genetic tests that claim to predict. Available at https://www.fda.gov. https://www.fda.gov/newsevents/press-announcements/jeffrey-shuren-md-jd-director-fdas-center-devices-and-radiological-health-and-janet-woodcock-md (accessed on 23 January 2020).

Fermier N, Bourguignon L, Goutelle S, Bleyzac N, Tod M. 2018. Identification of cytochrome P450-mediated drug–drug interactions at risk in cases of gene polymorphisms by using a quantitative prediction model. Clinical Pharmacokinetics 57:1581–1591 DOI 10.1007/s40262-018-0651-8.

Hefner G. 2018. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Psychopharmakotherapie 51:9–62 DOI 10.1055/s-0043-116492.
Hobson JA. 2005. Sleep is of the brain, by the brain and for the brain. *Nature* **437**:1254–1256 DOI 10.1038/nature04283.

Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. 2015. The glymphatic system: a beginner’s guide. *Neurochemical Research* **40**:2583–2599 DOI 10.1007/s11064-015-1581-6.

Lazowski LK, Townsend B, Hawken ER, Jokic R, Du Toit R, Miley R. 2014. Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial. *BMC Psychiatry* **14**:202 DOI 10.1186/1471-244X-14-202.

Macaluso M, Preskorn SH. 2018. Knowledge of the pharmacology of antidepressants and antipsychotics yields results comparable with pharmacogenetic testing. *Journal of Psychiatric Practice* **24**:416–419 DOI 10.1097/PRA.0000000000000345.

Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. 2011. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. *British Journal of Clinical Pharmacology* **72**:905–908 DOI 10.1111/j.1365-2125.2011.04037.x.

Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. 1997. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. *Journal of Pharmacology and Experimental Therapeutics* **283**:1305–1322.

Qin S, Eugene AR, Liu D, Zhang L, Neavin D, Biernacka JM, Yu J, Weinsilboum RM, Wang L. 2019. Dual roles for the TSPYL family in mediating serotonin transport and the metabolism of selective serotonin reuptake inhibitors in MDD patients. *Clinical Pharmacology and Therapeutics* **107**:662–670 DOI 10.1002/cpt.1692.

R Core Team. 2013. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Available at https://www.R-project.org/.

Roane BM, Taylor DJ. 2008. Adolescent insomnia as a risk factor for early adult depression and substance abuse. *Sleep* **31**(10):1351–1356 DOI 10.5665/sleep/31.10.1351.

Rochoy M, Zakhem-Stachera C, Béné J, Berkhout C, Gautier S. 2018. Antidepressive agents and hyponatremia: a literature review and a case/non-case study in the French Pharmacovigilance database. *Therapie* **73**:389–398 DOI 10.1016/j.therap.2018.02.006.

Roth BL, Lopez E, Patel S, Krozee WK. 2000. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? *Neuroscientist* **6**:252–262 DOI 10.1177/107385840000600408.

Sharpley AL, Elliott JM, Attenburrow MJ, Cowen PJ. 1994. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. *Neuropharmacology* **33**:467–471 DOI 10.1016/0028-3908(94)90077-9.

Szot P. 2016. Elevated cerebrospinal fluid norepinephrine in the elderly can link depression and a reduced glymphatic system as risk factors for alzheimer’s disease. *Journal of Aging Science* **4**:2 DOI 10.4172/2329-8847.1000158.

Tatsumi M, Groshan K, Blakely RD, Richelson E. 1997. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. *European Journal of Pharmacology* **340**:249–258 DOI 10.1016/S0014-2999(97)01393-9.
Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ. 2005. Epidemiology of insomnia, depression, and anxiety. *Sleep* 28:1457–1464 DOI 10.1093/sleep/28.11.1457.

Tran BX, Ha GH, Vu GT, Nguyen LH, Latkin CA, Nathan K, McIntyre RS, Ho CS, Tam WW, Ho RC. 2019. Indices of change, expectations, and popularity of biological treatments for major depressive disorder between 1988 and 2017: a scientometric analysis. *International Journal of Environmental Research and Public Health* 16: DOI 10.3390/ijerph16132255.

United States Food and Drug Administration. 2018. FDA Adverse Event Reporting System (FAERS) Public dashboard. Available at https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070093.htm.

Watson CJ, Baghdoyan HA, Lydic R. 2010. Neuropharmacology of sleep and wakefulness. *Sleep Medicine Clinics* 5:513–528 DOI 10.1016/j.jsmc.2010.08.003.

Watson CJ, Baghdoyan HA, Lydic R. 2012. Neuropharmacology of sleep and wakefulness: 2012 update. *Sleep Medicine Clinics* 7:469–486 DOI 10.1016/j.jsmc.2012.06.010.

White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. 1985. Comparative pharmacology of the ketamine isomers: studies in volunteers. *British Journal of Anaesthesia* 57:197–203 DOI 10.1093/bja/57.2.197.

Wong J, Motulsky A, Eguale T, Buckeridge DL, Abrahamowicz M, Tamblyn R. 2016. Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006–2015. *Journal of the American Medical Association* 315:2230–2232 DOI 10.1001/jama.2016.3445.

Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. 2013. Sleep drives metabolite clearance from the adult brain. *Science* 342:373–377 DOI 10.1126/science.1241224.

Yaya S, Wang R, Shangfeng T, Ghose B. 2018. Alcohol consumption and sleep deprivation among Ghanaian adults: ghana demographic and health survey. *PeerJ* 6:e5750 DOI 10.7717/peerj.5750.

Zhou Y, Ingelman-Sundberg M, Lauschke VM. 2017. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. *Clinical Pharmacology and Therapeutics* 102:688–700 DOI 10.1002/cpt.690.